Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,672 stopped studies mapped to Malignant Reproductive System Neoplasm and descendants · 89% state a reason
Over the 1,672 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04985357 | Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor… | — | withdrawn | Aug 2, 2021 | Travera Inc | Abandoned prior to launch. | Other (stated, no rule matched) |
| NCT03514121 | FPA150 in Patients With Advanced Solid Tumors(FPA150-001) | Early Phase 1 | terminated | May 2, 2018 | Five Prime Therapeutics, Inc. | The Sponsor terminated the study for reasons unrelated to safety. | Safety / toxicity |
| NCT05261490 | Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With… | Phase 1 / Phase 2 | terminated | Mar 2, 2022 | Pfizer | A business decision was made by Pfizer to terminate and remove the Phase 2 expansion of this study… | Safety / toxicity |
| NCT02588846 | Multi-target Tracking in Prostate Radiotherapy Using MLC and KIM(KOALA) | N/A | withdrawn | Oct 28, 2015 | Royal North Shore Hospital | no resources to run the trial | Other (stated, no rule matched) |
| NCT04493619 | PLX2853 as a Single Agent in Advanced Gynecological Malignancies and in Combination With… | Phase 1 / Phase 2 | terminated | Jul 30, 2020 | Opna Bio LLC | study terminated due to business realignment | Sponsor / business decision |
| NCT06034860 | Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With… | Phase 1 | terminated | Sep 13, 2023 | Molecular Templates, Inc. | Sponsor Termination | Other (stated, no rule matched) |
| NCT03990194 | Real-life Study of Patients After 3-months of Leuprorelin 5mg Implant in Prostate Cancer(LEPTO) | — | withdrawn | Jun 18, 2019 | RECORDATI GROUP | Internal decision | Other (stated, no rule matched) |
| NCT06218667 | A Study of Copanlisib in Combination with Degarelix in People with Prostate Cancer | Phase 1 / Phase 2 | withdrawn | Jan 23, 2024 | Memorial Sloan Kettering Cancer Center | Study drug not available per sponsor | Other (stated, no rule matched) |
| NCT02470585 | Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in…(VELIA) | Phase 3 | terminated | Jun 12, 2015 | AbbVie | Business decision not related to patient safety | Safety / toxicity |
| NCT06016504 | Adaptive Virtual Consultation Tool to Enhance Education and Understanding in Patients… | N/A | terminated | Aug 29, 2023 | Mayo Clinic | Low/slow accrual | Enrollment / accrual |
| NCT03240523 | A Study to Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids(ASTEROID 5) | Phase 3 | terminated | Aug 7, 2017 | Bayer | Due to a change in the development program, the study was closed prematurely. | Other (stated, no rule matched) |
| NCT04291664 | PK and Dose Escalation and Expansion Study of DST-2970 | Phase 1 | terminated | Mar 2, 2020 | DisperSol Technologies, LLC | Dose escalation portion of the study completed, one expansion cohort was eliminated due to change… | Enrollment / accrual |
| NCT05012397 | Milademetan in Advanced/Metastatic Solid Tumors | Phase 2 | terminated | Aug 19, 2021 | Rain Oncology Inc | Sponsor Decision | Sponsor / business decision |
| NCT03238053 | Laser Treatment of Genito-urinary Syndrome in Women | N/A | withdrawn | Aug 3, 2017 | Herning Hospital | Hospital terminated treatment with laser | Other (stated, no rule matched) |
| NCT04923672 | Exercise Preconditioning with Cancer Surgeries(ExPre 01) | N/A | terminated | Jun 11, 2021 | University of Virginia | Company providing the computer application for exercise intervention suddenly closed for business | Sponsor / business decision |
| NCT06161493 | ZEN003694 Combined With Niraparib in Patients With Metastatic or Recurrent Solid Tumors | Phase 1 | withdrawn | Dec 8, 2023 | Haider Mahdi | Investigator Discretion | Investigator |
| NCT05156905 | Study of Docetaxel Combined with Cirmtuzumab in Metastatic Castration Resistant Prostate… | Phase 1 | terminated | Dec 14, 2021 | University of California, San Diego | Oncternal closing clinical trial operations. | Other (stated, no rule matched) |
| NCT04312191 | Using Meditation for Oncology Anxiety | N/A | withdrawn | Mar 18, 2020 | Mellar Davis MD | Study was not started and PI is retiring. | Other (stated, no rule matched) |
| NCT03177187 | Combination Study of AZD5069 and Enzalutamide.(ACE) | Phase 1 / Phase 2 | terminated | Jun 6, 2017 | Institute of Cancer Research, United Kingdom | Discontinuation of production of IMP | Other (stated, no rule matched) |
| NCT03677024 | Evaluation of the Efficacy for Sentinel Lymph Node Policy in Intermediate-risk… | N/A | withdrawn | Sep 19, 2018 | Fudan University | This study was not approved by the Ethics Committee | Other (stated, no rule matched) |
| NCT06068738 | Association of Ex Vivo Drug Response (EVDR) and Clinical Outcome in Ovarian Cancer(EXCYTE-1) | — | terminated | Oct 5, 2023 | Exscientia AI Limited | Study was terminated due to a strategic re-evaluation of the company's overall business and… | Sponsor / business decision |
| NCT05707182 | 18F-rhPSMA-7.3 PET/MRI in Prostate Cancer Active Surveillance: a Pilot Study | Early Phase 1 | withdrawn | Jan 31, 2023 | University of Alabama at Birmingham | Recruitment was difficult. | Enrollment / accrual |
| NCT06099418 | Efficacy and Safety of VB10.16 Alone or in Combination With Atezolizumab in Patients With… | Phase 2 | withdrawn | Oct 25, 2023 | Nykode Therapeutics ASA | Trial VB-C-04 was stopped due to company strategic reasons and recent changes in standard of care… | Sponsor / business decision |
| NCT03459755 | Evaluating Race Specific AGE Accumulation As a Behavioral Biomarker Prostate Cancer… | N/A | withdrawn | Mar 9, 2018 | Medical University of South Carolina | investigator decision | Investigator |
| NCT03493464 | BR55 in Characterization of Ovarian Lesions | Phase 2 | terminated | Apr 10, 2018 | Bracco Diagnostics, Inc | Sponsor decision; expiration of available study agent due to long recruitment timeline. | Enrollment / accrual |
| NCT03691376 | Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan… | Phase 1 | terminated | Oct 1, 2018 | Roswell Park Cancer Institute | Lack of funding | Funding |
| NCT03777982 | Conventional Androgen Deprivation Therapy (ADT) With or Without Abiraterone Acetate +… | Phase 3 | terminated | Dec 19, 2018 | Dana-Farber Cancer Institute | PI is terminating the study due to slow/low accrual | Enrollment / accrual |
| NCT05655598 | TAS-116 Plus Palbociclib in Breast and Rb-null Cancer | Phase 1 | withdrawn | Dec 19, 2022 | Brown University | Lack of accrual | Enrollment / accrual |
| NCT05679388 | A Study of Extending Relugolix Dosing Intervals Through Addition of Itraconazole or… | Phase 1 | terminated | Jan 11, 2023 | University of Chicago | Terminated by the PI | Other (stated, no rule matched) |
| NCT05929300 | A Yoga Program for Patients Undergoing Prostate Cancer Surgery | N/A | withdrawn | Jul 3, 2023 | VA Office of Research and Development | Lack of recruitment | Enrollment / accrual |
| NCT06329830 | 177Lu-PSMA, Niraparib/AA Plus Prednisone for Prostate Cancer(LUNAAR) | Phase 1 / Phase 2 | withdrawn | Mar 26, 2024 | Baptist Health South Florida | Funding for the study was withdrawn. | Funding |
| NCT00773773 | Combination of Serum Measurements of Molecular Biomarkers and Serum Protein Profiling Can… | N/A | terminated | Oct 16, 2008 | Memorial Sloan Kettering Cancer Center | Protocol closed to accrual early due to PI retirement. | Enrollment / accrual |
| NCT03644342 | Study of Niraparib With Radiotherapy for Treatment of Metastatic Invasive Carcinoma of…(NIVIX) | Phase 1 / Phase 2 | terminated | Aug 23, 2018 | Michelle S Ludwig | A recent change in treatment landscape may make study futile | Other (stated, no rule matched) |
| NCT00321698 | Radiation Therapy and Docetaxel in Treating Patients Who Are Undergoing Surgery for… | Phase 1 / Phase 2 | terminated | May 4, 2006 | OHSU Knight Cancer Institute | Funding withdrawal | Funding |
| NCT03056638 | Trial of ADT and SBRT Versus SBRT for Intermediate Prostate Cancer | Phase 3 | terminated | Feb 17, 2017 | Memorial Sloan Kettering Cancer Center | Due to low accrual | Enrollment / accrual |
| NCT04248153 | Optimal Timing of BR55 CEUS of the Ovaries | Phase 2 | terminated | Jan 30, 2020 | Bracco Diagnostics, Inc | Sponsor decision; expiration of available study agent due to long recruitment timeline. | Enrollment / accrual |
| NCT04849858 | Pilot Study of Liposomal Bupivacaine Redosing in Patients Undergoing Major Gynecologic… | Phase 3 | terminated | Apr 19, 2021 | University of California, Irvine | Low recruitment | Enrollment / accrual |
| NCT01445275 | Cost of Cancer Risk Management in Women at Elevated Genetic Risk for Ovarian Cancer Who… | — | withdrawn | Oct 3, 2011 | Gynecologic Oncology Group | not stated | Not stated |
| NCT00819169 | QUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors | Phase 1 / Phase 2 | terminated | Jan 8, 2009 | NantCell, Inc. | Sponsor decision - subjects rolled over to protocol 20101116 | Sponsor / business decision |
| NCT04377087 | Delayed Initiation of Olaparib Maintenance Therapy in Platinum Sensitive Recurrent… | Phase 2 | terminated | May 6, 2020 | Sarah E Taylor | Slow enrollment | Enrollment / accrual |
| NCT06216561 | Intraperitoneal LSTA1 in CRS-HIPEC | Phase 1 | withdrawn | Jan 22, 2024 | University of California, San Diego | closed early due to low (0) accrual | Enrollment / accrual |
| NCT03850795 | HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Phase 3 | terminated | Feb 22, 2019 | Hinova Pharmaceuticals USA, Inc. | Terminated by Sponsor for various factors including prolonged duration and enrollment challenges | Enrollment / accrual |
| NCT01199250 | Biomarkers in Samples From Patients With Endometrial Cancer | — | withdrawn | Sep 10, 2010 | Gynecologic Oncology Group | Not a treatment/applicable clinical trial | Other (stated, no rule matched) |
| NCT06065059 | Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant… | Phase 1 / Phase 2 | terminated | Oct 3, 2023 | Tango Therapeutics, Inc. | Terminated due to safety | Safety / toxicity |
| NCT05084859 | A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally… | Phase 1 | terminated | Oct 20, 2021 | Biosplice Therapeutics, Inc. | Study was terminated due business reasons by Sponsor. | Sponsor / business decision |
| NCT05415696 | Prostatic Artery Embolization for the Treatment of Lower Urinary Tract Symptoms in… | N/A | withdrawn | Jun 13, 2022 | Stanford University | Enrolling to this clinical trial was too difficult | Enrollment / accrual |
| NCT05001282 | A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor… | Phase 1 / Phase 2 | terminated | Aug 11, 2021 | Elucida Oncology | Lack of Funding - no safety issue with Drug; Company Permanently Closed | Safety / toxicity |
| NCT03127098 | QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803… | Phase 1 / Phase 2 | terminated | Apr 25, 2017 | NantCell, Inc. | The study was terminated before any dose escalation occurred in order to pursue other studies… | Other (stated, no rule matched) |
| NCT00848601 | Safety of SGI-1776, A PIM Kinase Inhibitor in Refractory Prostate Cancer and… | Phase 1 | terminated | Feb 20, 2009 | Astex Pharmaceuticals, Inc. | The dose limiting toxicity of cardiac QTc prolongation was identifiedin the phase 1 study in… | Safety / toxicity |
| NCT04629781 | Open-label Dose Escalation Phase 1b Trial of a New Micellar Docetaxel Compound in… | Phase 1 | terminated | Nov 16, 2020 | Swiss Cancer Institute | SAKK decided to premature terminate this trial as additional follow-up visits do not further… | Efficacy / futility |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Nov 25, 2024source: clinicaltrials